Drug interactions between Actos and Lopid
Results for the following 2 drugs: |
|
|---|---|
| Actos (pioglitazone) | |
| Lopid (gemfibrozil) | |
Interactions between your selected drugs
gemfibrozil ↔ pioglitazone
Applies to:Lopid (gemfibrozil) and Actos (pioglitazone)
ADJUST DOSE: Coadministration with gemfibrozil may significantly increase the plasma concentrations of pioglitazone. The proposed mechanism is gemfibrozil inhibition of CYP450 2C8, the isoenzyme primarily responsible for the metabolic clearance of pioglitazone. In ten healthy volunteers, pretreatment with gemfibrozil (600 mg twice daily) for two days prior to coadministration of gemfibrozil and pioglitazone (30 mg orally) resulted in pioglitazone systemic exposure (AUC) that was 226% of that observed without gemfibrozil.
MANAGEMENT: Given the potential for dose-related adverse events with pioglitazone, a decrease in the pioglitazone dosage may be necessary when gemfibrozil is introduced. Close monitoring for the development of hypoglycemia and other adverse effects of pioglitazone such as fluid retention, heart failure, and pulmonary and peripheral edema is recommended. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
